Profiel
Michal Ayalon worked as Vice President of Research and Development at Kamada Ltd.
from 2019 to 2022.
Prior to that, she held the same position at Galmed Pharmaceuticals Ltd.
in 2015-2016.
In 2018-2019, she was Head of Research and Development at 89Bio Ltd.
Ayalon received her undergraduate, graduate, and doctorate degrees from Tel-Aviv University.
Eerdere bekende functies van Michal Ayalon
| Bedrijven | Functie | Einde |
|---|---|---|
| KAMADA LTD. | Hoofd Techniek/Wetenschap/O&O | 28-02-2022 |
89Bio Ltd.
 89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Hoofd Techniek/Wetenschap/O&O | 01-01-2019 |
| GALMED PHARMACEUTICALS LTD. | Hoofd Techniek/Wetenschap/O&O | 01-01-2016 |
Opleiding van Michal Ayalon
| Tel-Aviv University | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| GALMED PHARMACEUTICALS LTD. | Health Technology |
| KAMADA LTD. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
89Bio Ltd.
89Bio Ltd. Pharmaceuticals: MajorHealth Technology Part of 89bio, Inc., 89Bio Ltd. is an Israeli company that develops therapies and drugs for the treatment of patients living with nonalcoholic steatohepatitis. The company is based in Herzliya, Israel. | Health Technology |